Dabigatran

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Generic Name
Dabigatran
DrugBank Accession Number
DB14726
Background

Dabigatran is the active form of the orally bioavailable prodrug dabigatran etexilate.

Type
Small Molecule
Groups
Approved, Investigational
Structure
Thumb
Weight
Average: 471.521
Monoisotopic: 471.201887693
Chemical Formula
C25H25N7O3
Synonyms
  • Dabigatran
External IDs
  • BIBR 953 ZW
  • BIBR-953
  • BIBR-953-ZW

Pharmacology

Indication

Not Available

Pharmacology
Accelerate your drug discovery research with the industry’s only fully connected ADMET dataset, ideal for:
Machine Learning
Data Science
Drug Discovery
Accelerate your drug discovery research with our fully connected ADMET dataset
Learn more
Contraindications & Blackbox Warnings
Contraindications
Contraindications & Blackbox Warnings
With our commercial data, access important information on dangerous risks, contraindications, and adverse effects.
Learn more
Our Blackbox Warnings cover Risks, Contraindications, and Adverse Effects
Learn more
Pharmacodynamics

Not Available

Mechanism of action
Not Available
Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism
Not Available
Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects
Medicalerrors
Reduce medical errors
and improve treatment outcomes with our comprehensive & structured data on drug adverse effects.
Learn more
Reduce medical errors & improve treatment outcomes with our adverse effects data
Learn more
Toxicity

Not Available

Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
AbciximabThe risk or severity of bleeding can be increased when Abciximab is combined with Dabigatran.
AceclofenacThe risk or severity of bleeding and hemorrhage can be increased when Aceclofenac is combined with Dabigatran.
AcemetacinThe risk or severity of bleeding and hemorrhage can be increased when Acemetacin is combined with Dabigatran.
AcenocoumarolThe risk or severity of bleeding can be increased when Acenocoumarol is combined with Dabigatran.
Acetylsalicylic acidAcetylsalicylic acid may increase the anticoagulant activities of Dabigatran.
Albutrepenonacog alfaThe therapeutic efficacy of Albutrepenonacog alfa can be decreased when used in combination with Dabigatran.
AlclofenacThe risk or severity of bleeding and hemorrhage can be increased when Alclofenac is combined with Dabigatran.
AldesleukinThe risk or severity of bleeding can be increased when Dabigatran is combined with Aldesleukin.
AlemtuzumabThe risk or severity of bleeding can be increased when Dabigatran is combined with Alemtuzumab.
AlteplaseThe risk or severity of bleeding can be increased when Alteplase is combined with Dabigatran.
Interactions
Improve patient outcomes
Build effective decision support tools with the industry’s most comprehensive drug-drug interaction checker.
Learn more
Food Interactions
  • Avoid herbs and supplements with anticoagulant/antiplatelet activity. Examples include garlic, ginger, bilberry, danshen, piracetam, and ginkgo biloba.

Products

Products
Comprehensive & structured drug product info
From application numbers to product codes, connect different identifiers through our commercial datasets.
Learn more
Easily connect various identifiers back to our datasets
Learn more
International/Other Brands
Pradaxa

Categories

Drug Categories
Classification
Not classified
Affected organisms
Not Available

Chemical Identifiers

UNII
I0VM4M70GC
CAS number
211914-51-1
InChI Key
YBSJFWOBGCMAKL-UHFFFAOYSA-N
InChI
InChI=1S/C25H25N7O3/c1-31-20-10-7-17(25(35)32(13-11-23(33)34)21-4-2-3-12-28-21)14-19(20)30-22(31)15-29-18-8-5-16(6-9-18)24(26)27/h2-10,12,14,29H,11,13,15H2,1H3,(H3,26,27)(H,33,34)
IUPAC Name
3-[1-(2-{[(4-carbamimidoylphenyl)amino]methyl}-1-methyl-1H-1,3-benzodiazol-5-yl)-N-(pyridin-2-yl)formamido]propanoic acid
SMILES
CN1C(CNC2=CC=C(C=C2)C(N)=N)=NC2=C1C=CC(=C2)C(=O)N(CCC(O)=O)C1=NC=CC=C1

References

General References
Not Available
KEGG Drug
D09707
ChemSpider
187412
BindingDB
50112086
RxNav
1546356
ChEBI
70752
ChEMBL
CHEMBL48361
ZINC
ZINC000001910616
PDBe Ligand
4CC
Wikipedia
Dabigatran
PDB Entries
4jn2 / 4yhi / 4yhk / 4yhm / 4yho

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
4Active Not RecruitingOtherCerebral Ischemic Events / Cognition Disorders / Dementia1
4Active Not RecruitingPreventionAtrial Fibrillation1
4Active Not RecruitingPreventionAtrial Fibrillation / Device Related Thrombus / Left Atrial Appendage Thrombosis / Watchman LAA Closure Device1
4Active Not RecruitingTreatmentAtrial Fibrillation / Cardioembolic Events / Oral Anticoagulation1
4CompletedBasic ScienceAcute Coronary Syndrome (ACS) / Atrial Fibrillation1
4CompletedBasic ScienceVenous Thromboembolism1
4CompletedPreventionAtrial Fibrillation2
4CompletedTreatmentAtrial Fibrillation3
4CompletedTreatmentAtrial Fibrillation / Flutter, Atrial1
4CompletedTreatmentAtrial Fibrillation / Valvular Heart Disease1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.0975 mg/mLALOGPS
logP2.37ALOGPS
logP0.077ChemAxon
logS-3.7ALOGPS
pKa (Strongest Acidic)3.18ChemAxon
pKa (Strongest Basic)12.52ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count8ChemAxon
Hydrogen Donor Count4ChemAxon
Polar Surface Area150.22 Å2ChemAxon
Rotatable Bond Count9ChemAxon
Refractivity143.26 m3·mol-1ChemAxon
Polarizability50.96 Å3ChemAxon
Number of Rings4ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterNoChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleYesChemAxon
Predicted ADMET Features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
Not Available

Drug created on December 14, 2018 17:30 / Updated on June 26, 2021 13:10